Publications

5596 Results

Postoperative Complications Following Neoadjuvant Therapy and Surgery in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501)

Authors
R Snyder;S Ahmad;D Segovia;T Zemla;Q Shi;E O'Reilly;J Herman;M Katz
Journal / Conference
ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA); J Clin Oncol 42, 2024 (suppl 3; abstr 664), poster
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/A021501

Chemotherapy Dose Density is Prognostic for Patients with Resectable Pancreas Cancer: A Secondary Analysis of SWOG S1505

Authors
SH Patel;S Colby;D Sohal;K Guthrie;L Kachnic;E Chiorean;A Lowy;F Rocha;PA Philip;S Ahmad
Journal / Conference
Society of Surgical Oncology (March 20-23, 2024, Atlanta, GA) oral
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
S1505

Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505

Authors
J Cloyd;S Colby;K Guthrie;A Lowy;E Chiorean;P Philip;D Sohal;S Ahmad
Journal / Conference
Journal of the National Comprehensive Cancer Network Apr 29:1-6
Year
2024
Research Committee(s)
Gastrointestinal
PMID
PMID38688309
Study Number(s)
S1505

Body Composition Measurements and Clinical Outcomes in Patients with Resectable Pancreatic Adenocarcinoma – Analysis from SWOG S1505

Authors
D Sohal;K Guthrie;R Boutin;L Lenchik;J Kim;S Beg;A Wang-Gillam;J Wade;E Chiorean;S Ahmad;A Lowy;P Philip;V Chang
Journal / Conference
Journal of Gastrointestinal Surgery Mar;28(3):232-235
Year
2024
Research Committee(s)
Gastrointestinal
PMID
38445914
Study Number(s)
S1505

Adjuvant everolimus in patients with completely resected very high-risk renal cell cancer and clear cell histology: results from the phase III placebo-controlled SWOG S0931 (EVEREST) trial

Authors
P Lara;C Tangen;E Heath;S Gulati;M Stein;M Meng;A Alva;S Pal;I Puzanov;J Clark;T Choueiri;N Agarwal;R Uzzo;N Haas;T Synold;M Plets;U Vaishampayan;B Shuch;S Lerner;I Thompson;C Ryan
Journal / Conference
European Urology May 28:S0302-2838(24)02383-2
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID38811313
Study Number(s)
S0931

A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis

Authors
P Hagen;S Sidana;T Parker;A Hoering;V Sanchorawala;J Zonder;T Kourelis;A DSouza;H Landau;A Rosenthal;S Ailawadhi;R Orlowski;B Walker
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS7575)
Year
2024
Research Committee(s)
Myeloma
Study Number(s)
S2213

Effects of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes: Primary Results from the Randomized Phase III Double-Blind Clinical Trial (S1600)

Authors
J Hamilton-Reeves;J Unger;J Holzbeierlein;DL Lew;J Mark;S Daneshmand;J Kukreja;E Lee;W Tabayoyong;D Hershman;M Fisch;NL Henry
Journal / Conference
J Clin Oncol 42, 2024 (suppl 16; abstr 4501); ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), oral presentation, oral abstract session
Year
2024
Research Committee(s)
Symptom Management and Survivorship
Study Number(s)
S1600

Impact of the COVID-19 Pandemic on Data Quality in Cancer Treatment Trials: A Meta-Analysis of Sponsor-Level Aggregate Data

Authors
J Unger;H Andrews;L Levit;B McKelvey;M Stewart;E Dressler;K Flaherty;P Fredette;H (L) Jones;T Miller;A Onitilo;T Patel;S Bruinooge;L Garrett-Mayer;C Schenkel
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr 11021)
Year
2024
Research Committee(s)
Cancer Care Delivery

Patient-reported fatigue and risk of treatment-related adverse events (AEs) in patients receiving systemic therapy in cancer clinical trials

Authors
J Unger;R Vaidya;M Fisch;S Jones;NL Henry;D Hershman
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), Rapid Oral Abstract;J Clin Oncol 42, 2024 (suppl 16; abstr 11015)
Year
2024
Research Committee(s)
Symptom Management and Survivorship

Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-) node-positive breast cancer

Authors
L Pusztai;J Hoag;K Albain;W Barlow;S Stemmer;A Meisner;G Hortobagyi;S Shak;D Hayes;J Rae;R Baehner;P Sharma;K Kalinsky
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), oral; J Clin Oncol 42, 2024 (suppl 16; abstr 508)
Year
2024
Research Committee(s)
Breast
Study Number(s)
S1007, SWOG-8814